Trade Corvus Pharmaceuticals, Inc. - CRVS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0332 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.2084 |
| Open | 3.1384 |
| 1-Year Change | 120.28% |
| Day's Range | 3.1384 - 3.2584 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 3.2184 | 0.0500 | 1.58% | 3.1684 | 3.2584 | 3.1184 |
| Apr 16, 2025 | 3.2084 | 0.0300 | 0.94% | 3.1784 | 3.2584 | 3.0884 |
| Apr 15, 2025 | 3.2284 | 0.2200 | 7.31% | 3.0084 | 3.3484 | 2.9684 |
| Apr 14, 2025 | 3.0084 | 0.0000 | 0.00% | 3.0084 | 3.0484 | 2.9584 |
| Apr 11, 2025 | 2.9584 | 0.1300 | 4.60% | 2.8284 | 3.0084 | 2.7784 |
| Apr 10, 2025 | 2.8584 | -0.1000 | -3.38% | 2.9584 | 2.9684 | 2.7884 |
| Apr 9, 2025 | 2.9084 | 0.2800 | 10.65% | 2.6284 | 3.0384 | 2.5284 |
| Apr 8, 2025 | 2.7884 | -0.2400 | -7.92% | 3.0284 | 3.0384 | 2.7084 |
| Apr 7, 2025 | 2.8884 | 0.2500 | 9.48% | 2.6384 | 2.9284 | 2.5384 |
| Apr 4, 2025 | 2.8284 | -0.0300 | -1.05% | 2.8584 | 2.9384 | 2.6984 |
| Apr 3, 2025 | 2.9684 | -0.1000 | -3.26% | 3.0684 | 3.1084 | 2.9584 |
| Apr 2, 2025 | 3.1884 | 0.1000 | 3.24% | 3.0884 | 3.2884 | 3.0584 |
| Apr 1, 2025 | 3.1484 | 0.0700 | 2.27% | 3.0784 | 3.2284 | 3.0484 |
| Mar 31, 2025 | 3.1584 | -0.1500 | -4.53% | 3.3084 | 3.3184 | 3.0684 |
| Mar 28, 2025 | 3.3584 | -0.0100 | -0.30% | 3.3684 | 3.4284 | 3.2084 |
| Mar 27, 2025 | 3.3484 | 0.0600 | 1.82% | 3.2884 | 3.4084 | 3.2584 |
| Mar 26, 2025 | 3.3284 | -0.6500 | -16.34% | 3.9784 | 4.2684 | 3.1684 |
| Mar 25, 2025 | 3.9084 | -0.2100 | -5.10% | 4.1184 | 4.1884 | 3.7684 |
| Mar 24, 2025 | 4.2284 | -0.0800 | -1.86% | 4.3084 | 4.3884 | 4.0984 |
| Mar 21, 2025 | 4.2984 | 0.2400 | 5.91% | 4.0584 | 4.2984 | 3.9884 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Corvus Pharmaceuticals, Inc. Company profile
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression; and CPI-935, Adenosine A2B Receptor Antagonist.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Corvus Pharmaceuticals Inc revenues was not reported. Net loss increased from $6M to $43.2M. Higher net loss reflects Gain on deconsolidation of Angel Pharmac decrease from $37.5M (income) to $0K, Loss from equity method investment increase from $234K to $4.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.20 to -$1.03.
| Industry: | Biotechnology & Medical Research (NEC) |
863 Mitten Rd Ste 102
BURLINGAME
CALIFORNIA 94010-1311
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com